BEIJING -- A total of 13 rare-disease drugs have been added to the latest edition of China's medical insurance drug catalog, bringing the total amount of such medicines covered by medical insurance in the country to more than 90. The newly-added items on the catalog, which was jointly rel...
OK bill advances to help victims of rare disease gain insurance coverage
The Shenzhen Municipal Healthcare Security Bureau has worked to establish a rare disease medication security mechanism combining basic medical insurance, major disease insurance, and Shenzhen welfare insurance, which helps greatly r...
To alleviate the patients of their financial burdens, China has also expanded the coverage of its medical insurance. Earlier this year, 15 rare disease drugs have been incorporated into an updated catalog of medicines covered by China's national medical insurance, resulting in more urgently needed ...
We are an in-network provider with most commercial health insurance plans. Interested In Partnering? Contact Us Specialties Rare Disease Cardiology Pediatrics Neurology Oncology Services Genetic Counseling Genetic Test Ordering Clinical Trial Matching & Recruitment ...
Finally, due to the lack of data from the pre-implementation period, this study was unable to assess the impacts of the negotiation policy on the utilization and affordability of the rare disease drugs. Conclusion The health insurance reimbursement policy in a tier-one city has been operating ...
For drugs ready to go through negotiation/bidding, the experts will decide on their main strength, reference product, and insurance coverage scope. 2.4 Negotiation/Bidding (September-October 2022) Pharmaceutical companies submit documents for negotiation...
Expanding Horizons: Launching a Rare Disease Nonprofit Amid Government Funding Challenges November 17th 2023 Dr Jeffrey Sippel: The Impact of Insurance Denials for Patients With ALS November 15th 2023 Dr Ruben Mesa Shares How Atrium Health Addresses Health Disparities in Rural, Minority Populations Octob...
Rare disease (RD) management and orphan drug development in India face various hurdles regarding the implementation and adoption of comprehensive policies, lack of dedicated regulatory frameworks, and absence of epidemiological data. Current rare disease
New rare disease treatments are often approved more quickly through accelerated approval schemes, creating more uncertainties about clinical evidence and budget impact at the time of market entry. The use of real-world evidence (RWE), including early coverage with evidence development, has been ...